Kairos Pharma, LTD.
KAPA NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.56
KIRA · Stoqly’s AI analyst, in plain words
- Kairos Pharma, LTD. lost $5.4M in fiscal 2025.
Market cap
$12.0M
P/E
—
Revenue
—
Net income
−$5.4M
Free cash flow
—
Operating margin
—
Kairos Pharma, LTD. in 30 seconds · fiscal 2025
Does it make a profit?
−$5.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kairos Pharma, LTD. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Kairos Pharma, LTD.
- CIK
- 0001962011
Kairos Pharma, LTD. · KAPA
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$1.8M | −$2.6M | −$5.4M |
| Diluted EPS | −$0.17 | −$0.23 | −$0.30 |
| Cash | |||
| Cash from operations | $0.1M | −$4.0M | −$3.4M |
| Share count change | — | 9.4% | 62.3% |
| Debt and strength | |||
| Cash and short-term investments | $0.1M | $1.3M | $4.5M |
| Shareholders' equity | −$2.1M | $4.8M | $6.3M |
| Current ratio | 0.0x | 4.2x | 27.1x |
| Interest coverage | −40.8x | −66.9x | — |
| Returns and quality | |||
| Return on equity | — | −193.0% | −98.0% |
| Return on tangible equity | — | −57.2% | −86.7% |
| Altman Z'' | −49.3 | 1.0 | 25.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kairos Pharma, LTD. · KAPA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.56 a share, the company is worth $12.0M.
Source: SEC EDGAR XBRL filings (CIK 0001962011). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.